102 related articles for article (PubMed ID: 31126288)
1. Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial.
Banda CG; Chaponda M; Mukaka M; Mulenga M; Hachizovu S; Kabuya JB; Mulenga J; Sikalima J; Kalilani-Phiri L; Terlouw DJ; Khoo SH; Lalloo DG; Mwapasa V
Malar J; 2019 May; 18(1):180. PubMed ID: 31126288
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2018.
Ngasala B; Chiduo MG; Bushukatale S; Mmbando BP; Makene T; Kamugisha E; Ahmed M; Mandara CI; Francis F; Mahende MK; Kavishe RA; Muro F; Ishengoma DS; Mandike R; Molteni F; Chacky F; Kitojo C; Greer G; Bishanga D; Chadewa J; Njau R; Warsame M; Kabula B; Nyinondi SS; Reaves E; Mohamed A
Malar J; 2024 Apr; 23(1):95. PubMed ID: 38582830
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study.
Ogutu BR; Onyango KO; Koskei N; Omondi EK; Ongecha JM; Otieno GA; Obonyo C; Otieno L; Eyase F; Johnson JD; Omollo R; Perkins DJ; Akhwale W; Juma E
Malar J; 2014 Jan; 13():33. PubMed ID: 24472156
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019.
Ngasala BE; Chiduo MG; Mmbando BP; Francis FT; Bushukatale S; Makene T; Mandara CI; Ishengoma DS; Kamugisha E; Ahmed M; Mahende MK; Kavishe RA; Muro F; Molteni F; Reaves E; Kitojo C; Greer G; Nyinondi S; Kabula B; Lalji S; Chacky F; Njau RJ; Warsame M; Mohamed A
Malar J; 2024 Apr; 23(1):101. PubMed ID: 38594679
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy and tolerability of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020.
Laminou IM; Issa I; Adehossi E; Maman K; Jackou H; Coulibaly E; Tohon ZB; Ahmed J; Sanoussi E; Koko D
Malar J; 2024 May; 23(1):144. PubMed ID: 38741101
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021.
Dorkenoo AM; Warsame M; Ataba E; Hemou M; Yakpa K; Sossou E; Mitigmsagou M; Teou CD; Caspar E; Ma L; Djadou KE; Atcha-Oubou T; Rasmussen C; Menard D
Malar J; 2024 Apr; 23(1):92. PubMed ID: 38570791
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Artemisinin Combination Therapy for the treatment of uncomplicated Plasmodium falciparum malaria across international borders of India.
Sinha S; Sharma S; Singh K; Swarnkar D; Ahmed N; Rajput P; Srivastava B; Anvikar AR
J Vector Borne Dis; 2024 Jan; 61(1):81-89. PubMed ID: 38648409
[TBL] [Abstract][Full Text] [Related]
8. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda.
Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
PLoS One; 2024; 19(6):e0305064. PubMed ID: 38837973
[TBL] [Abstract][Full Text] [Related]
9. Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis.
Maiga FO; Wele M; Toure SM; Keita M; Tangara CO; Refeld RR; Thiero O; Kayentao K; Diakite M; Dara A; Li J; Toure M; Sagara I; Djimdé A; Mather FJ; Doumbia SO; Shaffer JG
Malar J; 2021 Aug; 20(1):356. PubMed ID: 34461901
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.
Bassat Q; Mulenga M; Tinto H; Piola P; Borrmann S; Menéndez C; Nambozi M; Valéa I; Nabasumba C; Sasi P; Bacchieri A; Corsi M; Ubben D; Talisuna A; D'Alessandro U
PLoS One; 2009 Nov; 4(11):e7871. PubMed ID: 19936217
[TBL] [Abstract][Full Text] [Related]
11. A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated Plasmodium falciparum in Nigeria.
Oyebola KM; Aina OO; Idowu ET; Olukosi YA; Ajibaye OS; Otubanjo OA; Awolola TS; Awandare GA; Amambua-Ngwa A
BMC Infect Dis; 2018 Aug; 18(1):392. PubMed ID: 30103683
[TBL] [Abstract][Full Text] [Related]
12. Failure of artemether-lumefantrine therapy in travellers returning to Belgium with Plasmodium falciparum malaria: an observational case series with genomic analysis.
Pierreux J; Bottieau E; Florence E; Maniewski U; Bruggemans A; Malotaux J; Martin C; Cox J; Konopnicki D; Guetens P; Verschueren J; Coppens J; Van Esbroeck M; Mutsaers M; Rosanas-Urgell A
J Travel Med; 2024 Apr; 31(3):. PubMed ID: 38157311
[TBL] [Abstract][Full Text] [Related]
13. Emergence of artemisinin-based combination treatment failure in patients returning from sub-Saharan Africa with P. falciparum malaria.
Grossman T; Vainer J; Paran Y; Studentsky L; Manor U; Dzikowski R; Schwartz E
J Travel Med; 2023 Dec; 30(8):. PubMed ID: 37606241
[TBL] [Abstract][Full Text] [Related]
14. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
Llanos-Cuentas A; Casapia M; Chuquiyauri R; Hinojosa JC; Kerr N; Rosario M; Toovey S; Arch RH; Phillips MA; Rozenberg FD; Bath J; Ng CL; Cowell AN; Winzeler EA; Fidock DA; Baker M; Möhrle JJ; Hooft van Huijsduijnen R; Gobeau N; Araeipour N; Andenmatten N; Rückle T; Duparc S
Lancet Infect Dis; 2018 Aug; 18(8):874-883. PubMed ID: 29909069
[TBL] [Abstract][Full Text] [Related]
15. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children.
Goodwin J; Kajubi R; Wang K; Li F; Wade M; Orukan F; Huang L; Whalen M; Aweeka FT; Mwebaza N; Parikh S
Nat Commun; 2024 May; 15(1):3817. PubMed ID: 38714692
[TBL] [Abstract][Full Text] [Related]
16. Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia.
Maude RJ; Tripura R; Ean M; Sokha M; Peto TJ; Callery JJ; Imwong M; Vongpromek R; Tarning J; Mukaka M; Waithira N; Soviet O; von Seidlein L; Sovannaroth S
BMJ Open; 2021 Jul; 11(7):e045900. PubMed ID: 34233975
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of
Lubis IND; Wijaya H; Lubis M; Lubis CP; Beshir KB; Staedke SG; Sutherland CJ
Open Forum Infect Dis; 2020 May; 7(5):ofaa116. PubMed ID: 32420402
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of artemether-lumefantrine for the treatment of uncomplicated
Ghimire P; Rijal KR; Kafle C; Karki BS; Singh N; Ortega L; Thakur GD; Adhikari B
Trop Dis Travel Med Vaccines; 2018; 4():9. PubMed ID: 30123520
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis.
Shibeshi W; Alemkere G; Mulu A; Engidawork E
BMC Infect Dis; 2021 Apr; 21(1):326. PubMed ID: 33827422
[TBL] [Abstract][Full Text] [Related]
20. Day 3 parasitemia and
Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
medRxiv; 2024 Apr; ():. PubMed ID: 38712186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
